SLC6A3 and Parkinson disease: A recent post-mortem study showed that within 4 years post-diagnosis, patients with Parkinson’s disease had an almost complete loss of TH-positive terminals and dopamine transporter immunohistochemistry in the dorsal putamen (Kordower et al., 2013).